Dr. Martens (DOCS) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
13 Jun, 2025Trading performance and outlook
Trading since the start of the financial year aligns with expectations, with FY25 guidance unchanged.
Q1 is the smallest period, marking the end of the Spring/Summer season.
The financial year is expected to be heavily weighted towards the second half, especially for profit.
Strategic focus and initiatives
The upcoming Autumn/Winter 24 season is a key focus, with detailed trading plans being implemented.
Targeting positive direct-to-consumer (DTC) growth in the USA during the second half.
Ongoing work on a cost action plan, with a detailed update to be provided at first half results in November.
Company background
Dr. Martens is a British brand founded in 1960, known for durable boots and cultural significance.
Listed on the London Stock Exchange since January 2021 and part of the FTSE 250 index.
Latest events from Dr. Martens
- FY27 guidance unchanged; trading and strategic objectives remain on track globally.DOCS
Trading update - Profit before tax up 61% with margin gains, strong cash flow, and growth in full-price sales.DOCS
H2 2026 - Wholesale gains and cost discipline drive profit outlook despite flat revenue and EMEA headwinds.DOCS
Q3 2026 TU - Gross margin rose to 65.3% and adjusted EBIT turned positive, led by strong DTC full price growth.DOCS
H1 2026 - Trading meets expectations, with growth in key regions and a focus on consumer-first strategy.DOCS
Trading Update - Revenue down 18%, losses posted, but cost savings and debt reduction support FY25 outlook.DOCS
H1 2025 - Consumer-first strategy and innovation drive profitable growth and global expansion ambitions.DOCS
Strategy Update - Q3 revenue up 3% CC, USA DTC grew 4%, APAC strong, EMEA flat amid high promotions.DOCS
Q3 2025 TU - Stabilized operations, cut costs, and reduced debt, setting up for growth despite lower revenue.DOCS
H2 2025